Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$416.12 USD

416.12
188,282

+2.11 (0.51%)

Updated Nov 4, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kaibalya Pravo Dey headshot

Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?

by Kaibalya Pravo Dey

Looking ahead to 2025, UNH projects adjusted earnings to reach around $30 per share at the top end, which falls short of the Zacks Consensus Estimate.

Zacks Industry Outlook Highlights Elevance Health, Doximity and HealthEquity

by Zacks Equity Research

Elevance Health, Doximity and HealthEquity are part of the Zacks Industry Outlook article.

Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations

by Zacks Equity Research

ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy to Navigate Industry Challenges

by Urmimala Biswas

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.

Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elevance Health (ELV) Q3 Earnings Lag Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of -13.71% and 3.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Elevance Health (ELV) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?

by Zacks Equity Research

ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.

Gear Up for Elevance Health (ELV) Q3 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add Elevance Health Stock to Your Portfolio

by Zacks Equity Research

ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Elevance Health Stock Has More to Offer: Should You Hold on Tight?

by Zacks Equity Research

In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.

Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?

by Zacks Equity Research

Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Elevance Health (ELV) Up 7.3% Since Last Earnings Report?

by Zacks Equity Research

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%

by Zacks Equity Research

Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat

by Zacks Equity Research

Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.

Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat

by Zacks Equity Research

Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.

Cigna (CI) Q2 Earnings Top on Specialty Business Strength

by Zacks Equity Research

Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.